Key statistics
As of last trade, 4D Molecular Therapeutics Inc (FDMT:NSQ) traded at 12.71, 34.67% above the 52 week low of 9.44 set on Oct 17, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 17.39 |
---|---|
High | 17.41 |
Low | 12.48 |
Bid | 12.64 |
Offer | 12.72 |
Previous close | 16.82 |
Average volume | 558.18k |
---|---|
Shares outstanding | 51.97m |
Free float | 50.16m |
P/E (TTM) | -- |
Market cap | 874.13m USD |
EPS (TTM) | -2.22 USD |
Data delayed at least 15 minutes, as of Sep 19 2024 16:11 BST.
More ▼
- 4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day
- 4DMT Announces Presentations at Upcoming Retina Conferences
- 4DMT to Participate in the 2024 Cantor Global Healthcare Conference
- 4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024
- 4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
- 4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights
- 4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board
- 4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity
- 4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy
- 4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast
More ▼